ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) and NeuroPace (NASDAQ:NPCE – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.
Profitability
This table compares ENDRA Life Sciences and NeuroPace’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ENDRA Life Sciences | N/A | -433.64% | -204.58% |
| NeuroPace | -21.67% | -108.20% | -18.50% |
Analyst Recommendations
This is a summary of current recommendations and price targets for ENDRA Life Sciences and NeuroPace, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ENDRA Life Sciences | 1 | 0 | 1 | 0 | 2.00 |
| NeuroPace | 1 | 1 | 4 | 2 | 2.88 |
Institutional and Insider Ownership
1.2% of ENDRA Life Sciences shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 10.0% of ENDRA Life Sciences shares are held by insiders. Comparatively, 20.5% of NeuroPace shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares ENDRA Life Sciences and NeuroPace”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ENDRA Life Sciences | N/A | N/A | -$7.03 million | ($8.15) | -0.56 |
| NeuroPace | $99.99 million | 5.33 | -$21.47 million | ($0.65) | -24.06 |
ENDRA Life Sciences has higher earnings, but lower revenue than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
ENDRA Life Sciences has a beta of -0.04, suggesting that its stock price is 104% less volatile than the S&P 500. Comparatively, NeuroPace has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500.
Summary
NeuroPace beats ENDRA Life Sciences on 10 of the 13 factors compared between the two stocks.
About ENDRA Life Sciences
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
About NeuroPace
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
